Portola Pharmaceuticals   Print Page    Close Window

Keyword Search
 
2018 | 2017 | 2016 | 2015
DateTitle 
December 03, 2018Updated Interim Results from Ongoing Phase 2a Study of Portola Pharmaceuticals’ Oral Syk/JAK Inhibitor Cerdulatinib Continues to Demonstrate Clinical Responses in Heavily Pre-Treated T-Cell MalignanciesPrinter Friendly Version
November 07, 2018Portola Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate UpdatePrinter Friendly Version
November 06, 2018Portola Pharmaceuticals to Participate in Two Upcoming Investor ConferencesPrinter Friendly Version
November 01, 2018Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Printer Friendly Version
November 01, 2018Portola Pharmaceuticals to Present New Interim Phase 2 Results for Cerdulatinib During an Oral Session at the 60th American Society of Hematology (ASH) Annual MeetingPrinter Friendly Version
October 23, 2018Portola Pharmaceuticals to Announce Third Quarter 2018 Financial Results and Host Conference Call on Wednesday, November 7, 2018Printer Friendly Version
October 09, 2018Portola Pharmaceuticals Supports 2018 World Thrombosis Day Campaign to Raise Awareness of Blood Clots as an Urgent and Growing Health CrisisPrinter Friendly Version
September 25, 2018Portola Pharmaceuticals Receives FDA Orphan Drug Designation for Cerdulatinib, an Oral Syk/JAK Inhibitor for the Treatment of Peripheral T-Cell LymphomaPrinter Friendly Version
September 20, 2018Portola Pharmaceuticals Names Scott Garland President and Chief Executive OfficerPrinter Friendly Version
September 11, 2018U.S. FDA Assigns PDUFA Date to Portola Pharmaceuticals’ Prior Approval Supplement for the Large-Scale Generation 2 Andexxa ProcessPrinter Friendly Version
September 07, 2018Portola Pharmaceuticals Announces Executive Leadership ChangePrinter Friendly Version
September 05, 2018Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Printer Friendly Version
August 31, 2018Portola Pharmaceuticals Submits Prior Approval Supplement to U.S. FDA for Large-Scale Generation 2 Andexxa ProcessPrinter Friendly Version
August 30, 2018Portola Pharmaceuticals to Participate in Two Upcoming Investor ConferencesPrinter Friendly Version
August 09, 2018Portola Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate UpdatePrinter Friendly Version
August 09, 2018Portola Pharmaceuticals Appoints Ernie Meyer as Executive Vice President and Chief Human Resources OfficerPrinter Friendly Version
August 03, 2018U.S. Centers for Medicare and Medicaid Services (CMS) Grants New Technology Add-On Payment for Portola Pharmaceuticals’ AndexxaPrinter Friendly Version
August 02, 2018Portola Pharmaceuticals to Announce Second Quarter 2018 Financial Results and Host Conference Call on Thursday, August 9, 2018Printer Friendly Version
July 27, 2018European CHMP Maintains Negative Opinion on Portola Pharmaceuticals’ Betrixaban Following AppealPrinter Friendly Version
July 03, 2018Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Printer Friendly Version
June 25, 2018Portola Pharmaceuticals Appoints 30-Year Industry Veteran Glenn Brame as Senior Vice President of Technical OperationsPrinter Friendly Version
June 05, 2018Portola Pharmaceuticals to Present at Two Upcoming Investor ConferencesPrinter Friendly Version
June 04, 2018Portola Pharmaceuticals Announces Retirement of CEO Bill Lis in 2018Printer Friendly Version
June 04, 2018New Interim Phase 2a Study Results Demonstrate Broad Clinical Activity of Portola Pharmaceuticals’ Oral SYK/JAK Inhibitor CerdulatinibPrinter Friendly Version
May 24, 2018Portola Pharmaceuticals Receives $100 Million Milestone Payment from HealthCare Royalty Partners for FDA Approval of Andexxa®Printer Friendly Version
May 09, 2018Portola Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate UpdatePrinter Friendly Version
May 03, 2018U.S. FDA Approves Portola Pharmaceuticals’ Andexxa®, First and Only Antidote for the Reversal of Factor Xa InhibitorsPrinter Friendly Version
April 30, 2018Portola Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 9, 2018Printer Friendly Version
April 25, 2018Portola Pharmaceuticals to Present New Interim Phase 2 Data for Cerdulatinib at the 2018 American Society of Clinical Oncology (ASCO) Annual MeetingPrinter Friendly Version
April 04, 2018Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Printer Friendly Version
March 23, 2018Portola Pharmaceuticals Receives and Plans to Appeal Negative CHMP Opinion Regarding Marketing Authorization for Betrixaban in the European UnionPrinter Friendly Version
March 12, 2018Portola Pharmaceuticals Announces New Interim Results from Ongoing ANNEXA-4 Study of Factor Xa Inhibitor Reversal Agent AndexXa® (Andexanet Alfa) in Patients with Life-Threatening BleedingPrinter Friendly Version
March 12, 2018Portola Pharmaceuticals Appoints Biotech Legal Veteran John Moriarty as Executive Vice President and General CounselPrinter Friendly Version
March 06, 2018Portola Pharmaceuticals to Present at Two Upcoming Investor ConferencesPrinter Friendly Version
March 05, 2018Portola Pharmaceuticals to Host Webcast Event and Conference Call at ACC.18 to Discuss Late-Breaking Oral Presentation Highlighting New Interim Data for Andexanet AlfaPrinter Friendly Version
February 28, 2018Portola Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate UpdatePrinter Friendly Version
February 20, 2018Portola Pharmaceuticals Announces Results of CHMP Oral Explanations for Andexanet Alfa and BetrixabanPrinter Friendly Version
February 15, 2018Portola Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Wednesday, February 28, 2018Printer Friendly Version
January 22, 2018Portola Pharmaceuticals Announces Acceptance of Late-Breaker Abstract Highlighting New Data for Andexanet Alfa at ACC.18Printer Friendly Version